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Supplementary Figures and Table 
The following materials are available in the online version of this article: 
Figure S1. Efficiencies of stable knock-downs, experimental design of in vitro differentiation 
model, and functional osteoclast activity in knock-down cells.   
Figure S2.  Timing of olaparib or IL-1β effect on multinucleation, and contribution of p65 on 
olaparib effect on multinucleation.   
Figure S3. Effect of NAC or merbarone on enhanced multinucleation by ARTD 
depletion/deletion.   
Figure S4.  ARTD1 deficiency causes osteopenia without changes in osteoblast parameters.   
Table S1.  List of real-time PCR and ChIP primer sequences.   
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Figure S1.  Efficiencies of stable knock-downs, experimental design of in vitro 
differentiation model, and functional osteoclast activity in knock-down cells.  (A) 
Efficiency of Artd1 and p65 silencing after RAW 264.7 macrophages transduction with 
retroviruses carrying shRNA was estimated using real-time PCR. Expression of Gapdh was 
used for normalization.  (B) Efficiency of Artd1 and p65 silencing with shRNA was 
determined at the level of protein by Western blotting. Tubulin was used as an internal 
control. (C) Experimental design of the in vitro differentiation model (upper panel). Graphic 
representation of osteoclast formation from RAW 264.7 macrophages; from the left: 
macrophages without RANKL treatment (-RANKL, day 0 (D0)), 2-day-old (D2) and 3-day-
old (D3) osteoclasts (lower panel).  (D) The resorbing activity of 3-day-old osteoclasts 
derived from shMOCK and shp65 macrophages were compared based on their capacity to 
induce matrix dissolution (resorption of bone-mimicking mineral surface) (left panel). The 
number of matrix dissolution spots was normalized to the number of multinucleated cells 
(right panel). (E) The functional activity of osteoclasts derived from shARTD1 RAW 264.7 
macrophages was verified based on their capacity to induce matrix dissolution.  
  
  
 
Figure S2. Timing of olaparib or IL-1β effect on multinucleation, and contribution of 
p65 on olaparib effect on multinucleation.  (A) Olaparib was administrated at selected time 
points after induction of osteoclastogenesis, and multinucleated cells were counted after 72 h. 
(B) IL-1β (2 ng/ml) was added at the indicated time points to shMOCK RAW 264.7 
macrophages cultured in the presence of RANKL, and multinucleated cells were quantified 
72 h after RANKL administration. (C) The contribution of p65 in the ADP-ribosylation-
mediated increase in osteoclast formation was studied in shMOCK and shp65 RAW 264.7 
macrophages induced to differentiate in the presence or absence of olaparib.  (D) The 
multinucleation of osteoclasts differentiated in the presence of medium conditioned by 
shMOCK and shp65 (± olaparib) was compared 48 h after RANKL administration.   
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Figure S3.  Effect of NAC or merbarone on enhanced multinucleation by ARTD 
depletion/deletion.  (A) The ROS scavenger N-acetylcysteine or (B) the topoisomerase II 
inhibitor merbarone were added together with RANKL to shMOCK and shARTD1 RAW 
264.7 macrophages and multinucleation was quantified 48 h later. (C) The topoisomerase II 
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inhibitor merbarone was added together with RANKL to the culture of WT and Artd1 (-/-) 
osteoclast precursors and multinucleation was quantified 48 h later. (D) The recovery of IL-1 
receptor 1 (IL-1r1) mRNA after silencing with siRNA was determined using real-time PCR. 
(E) The expression of NAFTc1/B and NAFTc1/C was compared between 3-day-old osteoclasts 
derived from shMOCK and shp65 (± olaparib) RAW 264.7 macrophages using real-time 
PCR. (F) The association of ARTD1 with chromatin in 3-day-old shMOCK (± olaparib) 
osteoclasts was determined by ChIP. (G) The double Artd1/p65 silencing with siRNA/shRNA 
over time was monitored with real-time PCR.  
  
  
 
Figure S4.  ARTD1 deficiency causes osteopenia without changes in osteoblast 
parameters.  Femurs of 8-week-old Artd1-deficient mice (n=4) and their wild-type 
littermates (n=4) were analysed by µCT.  (A) Trabecular number (Tb.N), thickness (Tb.Th) or 
spacing (Tb.Sp).  (B) Representative 3D reconstruction of mid-shaft cortical bone (left panels, 
size bars = 500 µm); cortical thickness (Ct.Th), cortical bone area and BMD were measured.  
(C) Osteoblast number/bone surface (OB.N/BS) or surface/bone/surface (OB.S/BS) was 
quantified from H&E stainings of tibial sections.  Values are mean ± SD.  * p<0.05, ** 
p<0.01. 
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Supplementary Table 
 
Table S1. List of real-time PCR and ChIP primer sequences 
Primers Sequence 
Used for 	  shRNA constructs 
Artd1 
Fwd 
GATCCCCGGTGATCGGTAGCAACAAATTCAAGAGATTTGTTGCTACCGATCACCTTTTTG
GAAA 
Artd1 
Rev 
AGCTTTTCCAAAAAGGTGATCGGTAGCAACAAATCTCTTGAATTTGTTGCTACCGATCAC
CGGG 
p65/RelA 
Fwd 
GATCCCCGAGTTTCAGCAGCTCCTGAACTTCAAGAGAGTTCAGGAGCTGCTGAAACTCT
TTTTGGAAA 
p65/RelA 
Rev 
AGCTTTTCCAAAAAGAGTTTCAGCAGCTCCTGAACTCTCTTGAAGTTCAGGAGCTGCTAA
ACTCGGG 
Used for real-time PCR 
Nfatc1/A 
Fwd GGTAACTCTGTCTTTCTAACCTTAAGCTC 
Nfatc1/A 
Rev GTGATGACCCCAGCATGCACCAGTCACAG 
Nfatc1/B 
Fwd CCCATCCGCCAGGCTACAGCCGCAGTAA 
Nfatc1/B 
Rev TTCGGTAAGTTGGGATTTCTGAGTGGTACC 
Nfatc1/C  
Fwd CCCATCCGCCAGGCTACAGCCGCAGTAA 
Nfatc1/C  
Rev TGAGTGGTACCAGATGTGGGTCCAGTTTAT 
Tracp 
Fwd AGATTTGTGGCTGTGGGCGA 
Tracp 
Rev CTGCACGGTTCTGGCGATCT 
Ctsk 
Fwd AAGTGGTTCAGAAGATGACGGGAC 
Ctsk Rev TCTTCAGAGTCAATGCCTCCGTTC 
Gapdh 
Fwd ACTCCACTCACGGCAAATTCA 
Gapdh 
Rev GGTCTCGCTCCTGGAAGATG 
p65/RelA 
Fwd GCGAGACCTGGAGCAAGCCATT 
p65/RelA 
Rev GTGTTGGGGGCCCGGTTATCAA 
Artd1 
Fwd GAAGGAAAGAGAAAAGGTGACG 
Artd1 
Rev GCAACTCTGTCCAAGATCGCTG 
IL-1b 
Fwd AAGGAGAACCAAGCAACGACAAAA 
IL-1b 
Rev TGGGGAACTCTGCAGACTCAAACT 
IL-1r1 
Fwd TGGAACAGAGCCAGTGTCAG 
IL-1r1 
Rev CAGGAGAAGTCGCAGGAAGT 
Rankl 
Fwd TGTACTTTCGAGCGCAGATG 
Rankl 
Rev AGGCTTGTTTCATCCTCCTG 
  
 
Dspp 
Fwd CCTCGGAGGCTTTGAAGACAT 
Dspp 
Rev CCTCTCGCATGTACCCCATC 
Opn 
Fwd TCCCTCGATGTCATCCCTGT 
Opn  
Rev ATCACATCCGACTGATCGGC 
Rank 
Fwd GCATCCCTTGCAGCTCAACA 
Rank 
Rev ATGGAAGAGCTGCAGACCAC 
Col1a1 
Fwd CGATGGATTCCCGTTCGAGT 
Col1a1 
Rev CGATCTCGTTGGATCCCTGG 
Used for ChIP 
IL-1b 
promoter 
Fwd 
CCCCTAAGAATTCCCATCAAGC 
IL-1b 
promoter 
Rev 
GAGCTGTGAAATTTTCCCTTGG 
Il6 body 
Fwd AAGTGGATTCCCACTGCCACACT 
Il6 body 
Rev ACAACAGGCAGCATCAGCTGACC 
